. 2020 Oct 22;3(10):e2022107. doi: 10.1001/jamanetworkopen.2020.22107

Table 3. Subgroup Analysis.

Variables	Without HPV			With HPV			HR (95% CI)
Variables	Events, No.	Person-years	Rate^a	Events, No.	Person-years	Rate^a	Crude	Adjusted^b	P value for interaction
Age, y
<20	2	164 071	0.12	2	168 429	0.12	0.97 (0.14-6.88)	0.58 (0.07-5.09)	.75
20-49	56	284 299	1.97	43	296 266	1.50	0.76 (0.51-1.13)	0.80 (0.53-1.20)
50-64	96	61 836	15.5	54	62 887	8.59	0.55 (0.40-0.77)^c	0.48 (0.34-0.68)^c
≥65	107	33 377	32.1	103	36 786	28.0	0.86 (0.66-1.13)	0.90 (0.69-1.19)
Sex
Women	133	289 595	4.59	94	291 606	3.22	0.70 (0.54-0.92)^d	0.73 (0.56-0.95)^e	.43
Men	128	253 989	5.04	108	262 763	4.11	0.81 (0.63-1.05)	0.71 (0.55-0.92)^d	.43
Comorbidity^f
No	27	412 227	0.65	20	413 263	0.48	0.73 (0.41-1.31)	0.77 (0.43-1.37)	.95
Yes	234	131 357	17.8	182	141 106	12.9	0.72 (0.60-0.88)^d	0.71 (0.58-0.86)^c	.95
Diabetes
No	128	532 245	2.40	109	542 630	2.01	0.83 (0.65-1.08)	0.85 (0.66-1.11)	.23
Yes	133	11 339	117.3	93	11 738	79.2	0.67 (0.51-0.87)^d	0.65 (0.50-0.85)^d	.23
Hepatitis C
No	257	540 042	4.76	192	550 946	3.48	0.73 (0.61-0.88)^d	0.71 (0.59-0.85)^c	.04
Yes	4	3542	11.3	10	3423	29.2	2.56 (0.80-8.15)	1.85 (0.54-6.39)	.04
Hepatitis B
No	251	530 319	4.73	195	540 270	3.61	0.76 (0.63-0.92)^d	0.72 (0.60-0.87)^c	.77
Yes	10	13 265	7.54	7	14 099	4.97	0.66 (0.25-1.73)	1.09 (0.38-3.14)	.77
Chronic kidney disease
No	184	541 047	3.40	130	551 780	2.36	0.69 (0.55-0.86)^d	0.64 (0.51-0.80)^d	.17
Yes	77	2537	30.5	72	2589	278.1	0.92 (0.66-1.26)	0.95 (0.68-1.32)	.17
NSAID use
No	70	285 202	2.49	35	254 620	1.37	0.55 (0.36-0.82)^d	0.53 (0.35-0.80)^d	.16
Yes	190	258 381	7.35	167	299 749	5.57	0.75 (0.61-0.93)^d	0.79 (0.64-0.97)^e	.16

Abbreviations: HPV, human papillomavirus; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drug.

^{^a}

Incidence rate per 10 000 person-years.

^{^b}

Multivariable analysis including age, comorbidities (ie, hypertension, diabetes, hyperlipidemia, coronary artery disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, chronic liver diseases, systemic lupus erythematosus, ankylosing spondylitis, rheumatoid arthritis, and hepatitis C), and use of statin, NSAID, or antihypertensive medications.

^{^c}

P < .001.

^{^d}

P < .01.

^{^e}

P < .05.

^{^f}

Individuals with any comorbidity (ie, hypertension, diabetes, hyperlipidemia, coronary artery disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, chronic liver diseases, systemic lupus erythematosus, ankylosing spondylitis, rheumatoid arthritis, Sjögren syndrome, hepatitis C, HIV, or hepatitis B) were classified into the comorbidity group.